Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5419989> ?p ?o }
Showing triples 1 to 53 of
53
with 100 triples per page.
- Q5419989 subject Q6762709.
- Q5419989 subject Q8301163.
- Q5419989 subject Q8403399.
- Q5419989 abstract "Exelixis is a genomics-based drug discovery company located in South San Francisco, Ca., and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. It works on the development of anti-cancer therapies. Exelixis has several compounds in various stages of FDA approval including : XL147 that targets phosphoinositide-3 kinase (PI3K); and XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway. XL880 (foretinib)The company also has various compounds in phase 1 clinical trials, including XL518 or GDC0973, a small molecule inhibitor of the MEK. Co-developed with Roche. XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors; XL139 that targets Hedgehog; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7; XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases.Its lead compound, XL184, has been approved for treatment of medullary thyroid cancer and is currently in a number of clinical trials for prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular, kidney. During its trial for the treatment of medullary thyroid cancer, XL184 was designated orphan drug status by the FDA and given the generic name, cabozantinib. Cabozantinib is an inhibitor of the tyrosine kinases Met and VEGFR2, and has been shown to abrogate tumor growth, metastasis, and angiogenesis.".
- Q5419989 foundingYear "1994".
- Q5419989 industry Q7108.
- Q5419989 location Q30.
- Q5419989 location Q927122.
- Q5419989 type Q891723.
- Q5419989 wikiPageExternalLink www.exelixis.com.
- Q5419989 wikiPageExternalLink www.exelixis.com.
- Q5419989 wikiPageWikiLink Q1367466.
- Q5419989 wikiPageWikiLink Q14875866.
- Q5419989 wikiPageWikiLink Q14876086.
- Q5419989 wikiPageWikiLink Q15708292.
- Q5419989 wikiPageWikiLink Q18028241.
- Q5419989 wikiPageWikiLink Q18032815.
- Q5419989 wikiPageWikiLink Q204711.
- Q5419989 wikiPageWikiLink Q222046.
- Q5419989 wikiPageWikiLink Q30.
- Q5419989 wikiPageWikiLink Q3493538.
- Q5419989 wikiPageWikiLink Q412555.
- Q5419989 wikiPageWikiLink Q423725.
- Q5419989 wikiPageWikiLink Q4650874.
- Q5419989 wikiPageWikiLink Q5469311.
- Q5419989 wikiPageWikiLink Q6593810.
- Q5419989 wikiPageWikiLink Q6762709.
- Q5419989 wikiPageWikiLink Q7108.
- Q5419989 wikiPageWikiLink Q7187512.
- Q5419989 wikiPageWikiLink Q795057.
- Q5419989 wikiPageWikiLink Q8301163.
- Q5419989 wikiPageWikiLink Q8403399.
- Q5419989 wikiPageWikiLink Q891723.
- Q5419989 wikiPageWikiLink Q927122.
- Q5419989 foundation "1994".
- Q5419989 homepage www.exelixis.com.
- Q5419989 industry Q7108.
- Q5419989 location Q30.
- Q5419989 location Q927122.
- Q5419989 name "Exelixis".
- Q5419989 type Q891723.
- Q5419989 type Organization.
- Q5419989 type Agent.
- Q5419989 type Company.
- Q5419989 type Organisation.
- Q5419989 type Agent.
- Q5419989 type SocialPerson.
- Q5419989 type Thing.
- Q5419989 type Q43229.
- Q5419989 comment "Exelixis is a genomics-based drug discovery company located in South San Francisco, Ca., and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. It works on the development of anti-cancer therapies.".
- Q5419989 label "Exelixis".
- Q5419989 homepage www.exelixis.com.
- Q5419989 name "Exelixis".